篇名 | Determinants of Treatment Modification in Hypercholesterolemic Patients |
---|---|
卷期 | 33:2 |
作者 | Ko-Fan Wang 、 Cheng-Hsueh Wu 、 Chun-Chin Chang 、 Lung-Ching Chen 、 Kang-Ling Wang 、 Tse-Min Lu 、 Shing-Jong Lin 、 Chern-En Chiang |
頁次 | 156-164 |
關鍵字 | Clinical inertia 、 Epidemiology 、 Hypercholesterolemia 、 Low-density lipoprotein cholesterol 、 Treatment modification 、 MEDLINE 、 SCI 、 Scopus |
出刊日期 | 201703 |
Background: There is a lack of knowledge of those contemporary factors associated with modifying subtherapeutic treatments in hypercholesterolemic patients. The aim of this study was to assess determinants of treatment modification in patients not attaining their low-density lipoprotein cholesterol goals. Methods: The CEntralized Pan-Asian survey on tHE Under-treatment of hypercholeSterolemia enrolled patients taking stable lipid-lowering medications. The study physicians then determined existing patient treatments, which were to be continued or modified when treatments failed. The patient questionnaire surveying patient attitudes and perceptions toward their hypercholesterolemia management was prospectively collected. The odds ratios (ORs) (95% confidence intervals) were calculated. Results: Among the 420 patients included for analysis, 35.7%were designated for planned treatment modification. Those patients assigned to treatment modificationwere more likely to have a family history of premature coronary heart disease (40% vs. 19%), an indication for secondary prevention (76% vs. 61%), elevated triglyceride (60% vs. 48%) and fasting sugar (84% vs. 67%), and were less adherent to their medications (29% vs. 12%) than patients assigned to treatment continuation. Patient recognition of treatment failure [OR, 1.82 (1.13-2.94)], the lower frequency of cholesterol checkup [OR, 2.40 (1.41-4.08)], patient satisfactionwith provided cholesterol information [OR, 2.30 (1.21-4.39)], and their feelings toward cholesterol management [OR, 0.25 (0.10-0.62) and 3.80 (2.28- 6.32)] for confusion and no strong feeling, respectivelywere determinants of the treatment modification assignment. Conclusions: Therewas a large gap between evidence-based goals and modification of subtherapeutic treatments, particularly among patients with lower treatment satisfaction and better compliance. Our findings have emphasized the need to further reduce inertia in implementing hypercholesterolemia management.